← Back to Search

Neuromodulation

Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder

Phase 3
Waitlist Available
Research Sponsored by Butler Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 6 months
Awards & highlights

Study Summary

This trial is testing whether transcranial magnetic stimulation, a non-invasive brain stimulation, can help treat OCD by changing the function of regions in the brain implicated in OCD.

Who is the study for?
This trial is for adults aged 18-70 with a primary diagnosis of OCD and moderate to severe symptoms. Participants must have stable mental health treatment, if any, for at least six weeks prior and be able to understand English. Exclusions include pregnancy, metal implants incompatible with MRI or TMS, acute suicidality, certain medical conditions like epilepsy or significant neurological issues, recent substance abuse, psychotic symptoms, and specific medication use.Check my eligibility
What is being tested?
The study tests how transcranial magnetic stimulation (TMS), a non-invasive brain modulation technique affects brain function in people with OCD. It aims to understand the changes in brain regions involved in OCD that could lead to future therapeutic applications.See study design
What are the potential side effects?
TMS may cause discomfort at the stimulation site on the scalp, headache or lightheadedness during or after treatment. Rarely it can induce seizures but this is uncommon especially when safety guidelines are followed.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Motor Cortex
Secondary outcome measures
Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCS)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Transcranial Magnetic StimulationExperimental Treatment1 Intervention
Transcranial Magnetic Stimulation applied over the pre-supplementary motor area (pSMA), for ten sessions, Monday through Friday, over the course of two weeks.

Find a Location

Who is running the clinical trial?

Harvard UniversityOTHER
229 Previous Clinical Trials
474,590 Total Patients Enrolled
University of PittsburghOTHER
1,712 Previous Clinical Trials
16,346,392 Total Patients Enrolled
6 Trials studying Obsessive-Compulsive Disorder
135 Patients Enrolled for Obsessive-Compulsive Disorder
University of Puerto RicoOTHER
62 Previous Clinical Trials
20,811 Total Patients Enrolled

Media Library

Transcranial Magentic Stimulation (Neuromodulation) Clinical Trial Eligibility Overview. Trial Name: NCT02704117 — Phase 3
Obsessive-Compulsive Disorder Research Study Groups: Transcranial Magnetic Stimulation
Obsessive-Compulsive Disorder Clinical Trial 2023: Transcranial Magentic Stimulation Highlights & Side Effects. Trial Name: NCT02704117 — Phase 3
Transcranial Magentic Stimulation (Neuromodulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02704117 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Which type of person is this research looking for?

"Up to 19 individuals that suffer from OCD and meet the following requirements will be accepted into this study: aged between 18-70, ability to communicate in English, no recent psychiatric medication use or stable usage for at least 6 weeks, a current primary diagnosis of OCD with Y-BOCS total score ≥16, ongoing psychotherapy allowed if established 3 months before study entry."

Answered by AI

Does this research project allow for participants who are over 35 years old?

"Eligibility criteria for this study include being above 18 years old and younger than 70."

Answered by AI

Could you please explain the risks associated with Transcranial Magnetic Stimulation?

"TMS has received a 3 from our team at Power. This is due to the fact that it is a phase 3 trial, so while there is some data supporting efficacy, there are also multiple rounds of data supporting safety."

Answered by AI

Is this study seeking more participants at this time?

"According to the latest information available on clinicaltrials.gov, this particular trial is not seeking any more patients at the moment. The original posting was on June 1st, 2015 but the listing was updated as recently as September 13th, 2022. There are 116 other trials that are looking for patients right now."

Answered by AI

Who else is applying?

What state do they live in?
Rhode Island
North Carolina
How old are they?
18 - 65
What site did they apply to?
Butler Hospital
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0
~2 spots leftby Mar 2025